Search

Your search keyword '"Shanley S"' showing total 3 results
Start Over Author "Shanley S" Publisher british medical association
3 results on '"Shanley S"'

1. Predicting the likelihood of carrying a BRCA1 or BRCA2 mutation: validation of BOADICEA, BRCAPRO, IBIS, Myriad and the Manchester scoring system using data from UK genetics clinics

Author

Antoniou, A.C., Hardy, R., Walker, L., Evans, D.G., Shenton, A., Eeles, R., Shanley, S., Pichert, G., Izatt, L., Rose, S., Douglas, F., Eccles, D., Morrison, P.J., Scott, J., Zimmern, R.L., Easton, D.F., and Pharoah, P.D.P.

Subjects
Genetic screening -- Usage, Genetic screening -- Reports, BRCA mutations -- Identification and classification, Breast cancer -- Risk factors, Examinations -- Validity, Examinations -- Reports, Health
Published
2008

2. The carrier clinic: an evaluation of a novel clinic dedicated to the follow-up of BRCA1 and BRCA2 carriers - implications for oncogenetics practice

Author

Bancroft, E.K., Locke, I., Ardern-Jones, A., D'Mello, L., McReynolds, K., Lennard, F., Barbachano, Y., Barwell, J., Walker, L., Mitchell, G., Dorkins, H., Cummings, C., Paterson, J., Kote-Jarai, Z., Mitra, A., Jhavar, S., Thomas S., Houlston, R., Shanley, S., and Eeles, R.A.

Subjects
BRCA mutations -- Identification and classification, BRCA mutations -- Demographic aspects, BRCA mutations -- Research, Breast cancer -- Risk factors, Breast cancer -- Research, Prostate cancer -- Risk factors, Prostate cancer -- Research, Sentinel health events -- Management, Company business management, Health
Published
2010

3. Psychosocial effects of whole-body MRI screening in adult high-risk pathogenic TP53 mutation carriers: a case-controlled study (SIGNIFY).

Author

Bancroft EK, Saya S, Brown E, Thomas S, Taylor N, Rothwell J, Pope J, Chamberlain A, Page E, Benafif S, Hanson H, Dias A, Mikropoulos C, Izatt L, Side L, Walker L, Donaldson A, Cook JA, Barwell J, Wiles V, Limb L, Eccles DM, Leach MO, Shanley S, Gilbert FJ, Gallagher D, Rajashanker B, Whitehouse RW, Koh DM, Sohaib SA, Evans DG, Eeles RA, and Walker LG

Subjects
Adult, Female, Genetic Predisposition to Disease, Germ-Line Mutation genetics, Heterozygote, Humans, Li-Fraumeni Syndrome diagnostic imaging, Li-Fraumeni Syndrome genetics, Li-Fraumeni Syndrome pathology, Male, Middle Aged, Neoplasms diagnostic imaging, Neoplasms genetics, Neoplasms pathology, Risk Factors, Whole Body Imaging, Young Adult, Li-Fraumeni Syndrome diagnosis, Magnetic Resonance Imaging, Neoplasms diagnosis, Tumor Suppressor Protein p53 genetics
Abstract

Background: Germline TP53 gene pathogenic variants (pv) cause a very high lifetime risk of developing cancer, almost 100% for women and 75% for men. In the UK, annual MRI breast screening is recommended for female TP53 pv carriers. The SIGNIFY study (Magnetic Resonance Imaging screening in Li Fraumeni syndrome: An exploratory whole body MRI) study reported outcomes of whole-body MRI (WB-MRI) in a cohort of 44 TP53 pv carriers and 44 matched population controls. The results supported the use of a baseline WB-MRI screen in all adult TP53 pv carriers. Here we report the acceptability of WB-MRI screening and effects on psychosocial functioning and health-related quality of life in the short and medium terms., Methods: Psychosocial and other assessments were carried out at study enrolment, immediately before MRI, before and after MRI results, and at 12, 26 and 52 weeks' follow-up., Results: WB-MRI was found to be acceptable with high levels of satisfaction and low levels of psychological morbidity throughout. Although their mean levels of cancer worry were not high, carriers had significantly more cancer worry at most time-points than controls. They also reported significantly more clinically significant intrusive and avoidant thoughts about cancer than controls at all time-points. There were no clinically significant adverse psychosocial outcomes in either carriers with a history of cancer or in those requiring further investigations., Conclusion: WB-MRI screening can be implemented in TP53 pv carriers without adverse psychosocial outcomes in the short and medium terms. A previous cancer diagnosis may predict a better psychosocial outcome. Some carriers seriously underestimate their risk of cancer. Carriers of pv should have access to a clinician to help them develop adaptive strategies to cope with cancer-related concerns and respond to clinically significant depression and/or anxiety., Competing Interests: Competing interests: RAE: (1) GU-ASCO meeting in San Francisco, January 2016: honorarium as speaker, $500; (2) Royal Marsden NHS Foundation Trust talk (Title: Genetics and Prostate Cancer), November 2017: £1100 support from Janssen; and (3) University of Chicago invited talk, May 2018: honorarium as speaker, $1000., (© Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.)

Published
2020
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results